Hologic (NASDAQ:HOLX) Earns Outperform Rating from William Blair

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "outperform" rating reaffirmed by research analysts at William Blair in a research report issued to clients and investors on Thursday,RTT News reports. William Blair also issued estimates for Hologic's Q3 2025 earnings at $1.12 EPS, Q4 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.17 EPS, Q4 2026 earnings at $1.17 EPS and FY2026 earnings at $4.55 EPS.

Several other research firms have also commented on HOLX. Needham & Company LLC lowered Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $80.00 to $75.00 in a report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. BNP Paribas raised shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Evercore ISI decreased their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $85.77.

Hologic Price Performance

NASDAQ HOLX traded up $0.66 during trading on Thursday, hitting $65.24. 3,020,034 shares of the stock traded hands, compared to its average volume of 2,581,862. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic has a 12-month low of $63.62 and a 12-month high of $84.67. The firm has a 50-day simple moving average of $72.33 and a 200-day simple moving average of $77.76. The company has a market capitalization of $14.73 billion, a P/E ratio of 20.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts predict that Hologic will post 4.27 EPS for the current year.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.88% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Sanctuary Advisors LLC purchased a new position in Hologic in the second quarter worth $1,212,000. Czech National Bank boosted its position in shares of Hologic by 6.4% in the 3rd quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider's stock worth $3,854,000 after purchasing an additional 2,843 shares in the last quarter. GAMMA Investing LLC increased its position in Hologic by 17.9% during the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock valued at $312,000 after buying an additional 582 shares in the last quarter. Marcum Wealth LLC purchased a new stake in Hologic in the third quarter valued at about $202,000. Finally, Wedmont Private Capital boosted its holdings in Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock worth $361,000 after acquiring an additional 162 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.